

ASX Announcement

Date of AGM and Closing Date for Director Nominations

5 October 2026

Racura Oncology Limited (“Racura” or the “Company”) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting is to be held at 12.00 noon AEDT on Monday, 23 November 2026 at the Library Auditorium, State Library NSW, 1 Shakespeare Place, Sydney, New South Wales, Australia.

An item of business at the AGM will be the re-election and appointment of Directors. In accordance with clause 15.3 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Monday, 12 October 2026.

Any nominations must be received by the Company in writing by no later than 5.00 pm AEDT on Monday, 12 October 2026.

– ENDS –

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily acts through G4-DNA and RNA binding, resulting in potent silencing of MYC, an important regulator of cancer growth. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile. Recent Racura discoveries have enabled composition of matter IP filings that may provide 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing RC220, a proprietary formulation of (E,E)-bisantrene, to address significant unmet needs across multiple oncology indications. Its clinical programs include a Phase 3 program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program combining RC220 with doxorubicin, where Racura aims to deliver both cardioprotection and enhanced anticancer activity for patients with solid tumours.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. Racura is

actively exploring partnerships, licence agreements and commercial merger and acquisition opportunities to accelerate global access to RC220 for patients with cancer. Learn more at www.racuraoncology.com.

For questions about this announcement or previous Racura Oncology announcements, please visit our [Interactive Announcements](#) page.

Racura encourages investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au